Royalty Report: Drugs, Cancer, Biotechnology – Collection: 227239

License Grant

The Canadian Licensor hereby grants to the Canadian Licensee and Licensee hereby accepts (a) in consideration of the up-front payment under hereof, an exclusive worldwide right and license under the Patent Rights, and (b) in consideration of the Net Sales Revenue Royalty hereof, an exclusive worldwide right and license under the Proprietary Rights, exclusive of the Patent Rights, in either case (being (a) or (b) above) to use the B43 Antibody, the B43 Working Cell Bank, and the Data to develop, commercialize, manufacture, make, use and sell Licensed Products solely for Anti-Idiotype Applications, including the right to grant sublicenses to third parties, subject to the terms and conditions of this Agreement.

License Property

Patent Rights means the patent applications referred to this Agreement, together with all continuations, divisionals, continuations-in-part, and any foreign equivalents, and any patents issuing therefrom, including any reissues thereof, related to the Licensed Products and Technology;

Proprietary Rights means the Patent Rights and all copyrights, trademarks, industrial designs and other intellectual property rights or benefits (including Know-How) specifically relating to Anti-Idiotype Applications of the B43 Antibody, the B43 Working Cell Bank and the Data, in each case owned or controlled by Licensor, but excluding the Multi-Epitopic Patent Rights;

Data means, as of November 24, 1995 (the effective date of the Original Agreement), the experimental and clinical data and records of Licensor relating to the B43 Antibody, the B43 Working Cell Bank and the product OVAREX(TM) owned by Licensor;

B43 Antibody means the murine antibody MAb B43.13

MAb-B43 relates to anti-idiotype applications.

B43 Working Cell Bank means Licensors murine working hybridoma cell bank B43.13 of the murine hybridoma clone B43.13 such cell bank being produced at the Charles River Laboratories and used in the OVAREX(TM) program as of November 24, 1995 (the effective date of the Original Agreement);

Anti-Idiotype Applications means the induction of anti-idiotype and/or cellular immune response by administration of a formulation containing an antibody, antibody fragment or antibody derivative for the treatment or prevention of disease. Without limiting the generality of the foregoing, Anti-Idiotype Applications specifically includes the administration of the B43 Antibody for therapeutic or prophylactic purposes;

Field of Use

OvaRex(TM) is based on Licensee's proprietary antibody-based immunotherapeutic approach known as Anti-idiotype Induction Therapy.  Treatment with OvaRex(TM) MAb in late stage ovarian cancer patients with residual disease has been well tolerated in an ongoing open label Phase II study.

License Grant

The Canadian Licensor hereby grants to Licensee a sole and exclusive, non-transferable (other than to an Affiliate with prior written notice to Licensor), royalty bearing license in the Territory, with the right to grant sublicenses, under the Licensed Technology to develop, make, have made, use, import, market, promote, sell and have sold Products within the Field in the Territory.

License Property

Licensor has rights to certain antigen-targeted antibodies that may be effective in the treatment of certain diseases.

Licensed Technology means, collectively, (j) OvaRex®, BrevaRex®, ProstaRex™, AR54, and GivaRex™ their formulations and methods of administration; (k) the Prior Development Technology; (l) Patents, Know-How, and Joint Intellectual Property, (m) all Information relating to those certain antibodies known as OvaRex®, BrevaRex®, ProstaRex™, AR54, and GivaRex™ in the course of any work conducted pursuant to this Agreement, and (n) Improvements.

Therapeutic composition that produce an immune response Altered Immunogenicity USA 9/2/98 09/152,698

Therapeutic Binding Agents against MUC-1 antigen and methods of their use BrevaRex  USA 8/18/00  09/641,833 & USA 11/26/01 09/994,466

Therapeutic method utilizing antigen-antibody complexation and presentation by dendritic cells-Dendritic Cells.

OvaRex   listen (OH-vuh-REX)  A monoclonal antibody that is being studied in the treatment of ovarian cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. OvaRex binds to the CA-125 antigen, which is found on most ovarian cancer cells. Also called oregovomab.

BrevaRex A phase-II trial, activated murine monoclonal antibody developed for treating tumours expressing MUC-1—e.g., breast, prostate, pancreas, renal, lung and colorectal cancers.

ProstaRex(TM) MAb to induce T cells in laboratory studies to a circulating prostate cancer antigen, PSA.

GIVAREX is a product related to gastrointestinal cancer vaccine based on a murine monoclonal antibody and a gastrointestinal cancer pharmaceutical preparations for vaccination consisting of the monoclonal antibody supplied in a proprietary formulation for intravenous, subcutaneous, intraperitoneal or intramuscular injection in humans.

Field of Use

Field means the treatment of any and all therapeutic indications and uses.

Licensee is involved in the development and commercialization of products potentially useful in the prevention, mitigation and treatment of disease.

License Grant

Japanese Licensor grants to Licensee and its Affiliates the sole and exclusive, world-wide, royalty-bearing, assignable license under the Licensed Patents and Related Materials, with right to sublicense in one or more tiers of sublicenses, to research, develop, make, have made, use, sell, offer for sale, and import products and/or services in any and all fields of use or application.

License Property

Licensor owns certain rights in and to certain patents, information and materials related to the human antibody Pritumumab and a sister antibody to Pritumumab.

Licensed Patents
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5

4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells

5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins

5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas

5,286,647 – human-human hybridomas for neoplasms

5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.

5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.

6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions

6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies

6,051,693 – CLNH11-specific antibodies

6,090,924 – human-human CLNH5-specific antibodies

6,165,467 – stabilized human monoclonal antibody preparation

Field of Use

Pritumumab is a human monoclonal antibody[1] used in the treatment of brain cancer.

The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company